Stockscreener 앱 받기
1.23
1.65%
0.02
전일 마감가:
$1.21
열려 있는:
$1.22
하루 거래량:
2.14M
Relative Volume:
0.66
시가총액:
$944.27M
수익:
$711.41M
순이익/손실:
$-133.73M
주가수익비율:
-6.4737
EPS:
-0.19
순현금흐름:
$-199.99M
1주 성능:
-0.81%
1개월 성능:
-8.21%
6개월 성능:
-8.89%
1년 성능:
-25.90%
1일 변동 폭
$1.21
$1.27
1주일 범위
$1.20
$1.27
52주 변동 폭
$1.11
$2.035
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.23 | 928.92M | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | JP Morgan | Neutral |
| 2025-10-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-25 | 개시 | JP Morgan | Neutral |
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
Why OPKO Health Inc. stock is favored by top institutionsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - OPKO Health, Inc.
What is the long term forecast for OPKO Health Inc. stockWall Street Watch & AI Enhanced Trade Execution Alerts - mfd.ru
OPKO Health Insider Ups Holding During Year - Yahoo Finance
What hedge fund activity signals for OPKO Health Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Opko Health stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Swing Trade: What is OPKO Health Incs 5 year growth outlookWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism - marketscreener.com
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism - TradingView
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Market Review: Is OPKO Health Inc likely to announce a buybackJuly 2025 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha
EV Market: Will OPKO Health Inc benefit from seasonality2025 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Analyst Calls: Does RAMP align with a passive investing strategyCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts - MarketBeat
OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Update Recap: What is OPKO Health Incs 5 year growth outlookJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Movement Recap: What drives Simulations Plus Incs stock priceQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Opko Health, Inc. (OPK) Stock Analysis: Exploring A Potential 177.99% Upside - DirectorsTalk Interviews
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burg... - ADVFN
Options Flow: What is the long term forecast for OPKO Health Inc stockPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health (NASDAQ:OPK) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
OPK: Therapeutics-focused strategy, key partnerships, and innovative pipeline drive growth - TradingView — Track All Markets
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns - Yahoo Finance
Block Trades: Is OPKO Health Inc forming a double bottom2025 AllTime Highs & Accurate Buy Signal Notifications - baoquankhu1.vn
Assessing OPKO Health (OPK) Valuation After Diagnostics Refocus And Mixed Share Price Performance - Yahoo Finance
What are the future prospects of OPKO Health Inc.Exit Point & Smart Allocation Stock Tips - bollywoodhelpline.com
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 167% Potential Upside For Investors - DirectorsTalk Interviews
Bearish Setup: Should I hold or sell OPKO Health Inc nowWeekly Stock Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Is OPKO Health Inc. stock undervalued vs historical averagesQuarterly Trade Summary & Low Risk Investment Opportunities - ulpravda.ru
Is OPKO Health Inc. stock vulnerable to regulatory risks2025 Dividend Review & Advanced Technical Analysis Signals - Улправда
Is OPKO Health Inc. stock supported by innovation pipelineShare Buyback & Real-Time Chart Pattern Alerts - Улправда
Why OPKO Health Inc. stock is considered a top pick2025 Fundamental Recap & Weekly Watchlist for Hot Stocks - Улправда
Is OPKO Health Inc. stock attractive for income investorsQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - Улправда
Setup Watch: Why OPKO Health Inc. stock appeals to analystsTrade Risk Assessment & Weekly High Return Forecasts - Улправда
Does OPKO Health Inc. stock trade at a discount to peersJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
How OPKO Health Inc. (XCY) stock trades after earningsEarnings Forecast Updates & Low Entry Cost Investments - Улправда
OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap - simplywall.st
Clinical Laboratory Services Market is expected to reach US$ - openPR.com
Why OPKO Health Inc. stock is rated strong buyPrice Gap Trading Strategies & Free Phenomenal Capital Appreciation - bollywoodhelpline.com
What risks investors should watch in OPKO Health Inc. stockSector Rotation Strategies & Big Gains Small Capital - ulpravda.ru
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opko Health Inc 주식 (OPK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 10 '25 |
Buy |
1.36 |
125,000 |
169,712 |
214,001,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
0.00%
1.13%
자본화:
|
볼륨(24시간):